CTLA4 and colorectal adenocarcinoma: A clinical trial has shown that hypofractionated radiation therapy (3 fractions of 8 Gy) combined with anti-PD-L1-antibody or anti-CTLA-4 antibody could induce the proliferation of CD8+ T-cell and increase of M1/M2 macrophage ratios in patients with metastatic microsatellite stable colorectal adenocarcinoma (19).